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Dynamic changes in Mcl-1 expression
regulate macrophage viability or commitment
to apoptosis during bacterial clearance
Helen M. Marriott,1 Colin D. Bingle,1 Robert C. Read,1 Karen E. Braley,2 Guido Kroemer,3
Paul G. Hellewell,4 Ruth W. Craig,2 Moira K.B. Whyte,1 and David H. Dockrell1
1Division

of Genomic Medicine, University of Sheffield, Sheffield, United Kingdom. 2Department of Pharmacology and Toxicology,
Dartmouth Medical School, Hanover, New Hampshire, USA. 3Centre National de la Recherché Scientifique, UMR 8125,
Institut Gustave Roussy, Villejuif, France. 4Division of Clinical Sciences North, University of Sheffield, Sheffield, United Kingdom.

Macrophages are critical effectors of bacterial clearance and must retain viability, despite exposure to toxic bacterial products, until key antimicrobial functions are performed. Subsequently, host-mediated macrophage
apoptosis aids resolution of infection. The ability of macrophages to make this transition from resistance to
susceptibility to apoptosis is important for effective host innate immune responses. We investigated the role of
Mcl-1, an essential regulator of macrophage lifespan, in this switch from viability to apoptosis, using the model
of pneumococcal-associated macrophage apoptosis. Upon exposure to pneumococci, macrophages initially
upregulate Mcl-1 protein and maintain viability for up to 14 hours. Subsequently, macrophages reduce expression of full-length Mcl-1 and upregulate a 34-kDa isoform of Mcl-1 corresponding to a novel BH3-only splice
variant, Mcl-1Exon-1. Change in expression of Mcl-1 protein is associated with mitochondrial membrane permeabilization, which is characterized by loss of mitochondrial inner transmembrane potential and translocation of
cytochrome c and apoptosis-inducing factor. Following pneumococcal infection, macrophages expressing fulllength human Mcl-1 as a transgene exhibit a delay in apoptosis and in bacterial killing. Mcl-1 transgenic mice
clear pneumococci from the lung less efficiently than nontransgenic mice. Dynamic changes in Mcl-1 expression
determine macrophage viability as well as antibacterial host defense.
Introduction
Macrophages are the resident professional phagocytes in noninflamed tissues and survive in situ for extended periods of time (1).
In keeping with this phenotype, macrophages exhibit inherent
resistance to apoptosis and maintain viability in the presence of
proapoptotic factors (2). Bacterial infection is a potent stimulus
for apoptosis, and microbial virulence factors inhibit macrophage
viability to impede antibacterial defenses (3). Surprisingly, macrophage apoptosis can also facilitate immune responses by limiting bacterial replication (4). This apparent paradox suggests that
optimal macrophage antibacterial responses require transient
maintenance of cell viability in the face of proapoptotic stimuli,
followed by apoptosis induction for maximal bacterial clearance
and minimal immune-mediated tissue injury. The control of this
switch in macrophage phenotype is therefore an essential regulator of innate host defense.
The molecular basis of macrophage resistance to apoptosis
includes expression of antiapoptotic Bcl-2 family members, among
which Mcl-1 predominates in differentiated human macrophages
(2). Mcl-1 was first identified as a molecule that is upregulated
Nonstandard abbreviations used: AIF, apoptosis-inducing factor; AM, alveolar
macrophage; BMDM, bone marrow–derived macrophage; EGFP, enhanced GFP;
JC-1, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide;
Δψm, mitochondrial inner transmembrane potential; MDM, monocyte-derived macrophage; MG-132, carbobenzoxy-L-leucyl-L-leucyl-L-leucinal; MMP, mitochondrial
membrane permeabilization; zVADfmk, N-benzyloxycarbonyl–Val-Ala-Asp (O-methyl)
fluoromethyl ketone.
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during differentiation of immature myeloid cells along the monocyte/macrophage pathway (5). It is unique among antiapoptotic
members of the Bcl-2 family in that it is an early-response gene that
can be rapidly induced and turned over (6, 7). Mcl-1 is expressed
during critical transitions in cell phenotype and protects against
apoptosis during the initial steps of differentiation, exposure to
growth stimuli, or the rapid response to potentially cytotoxic
stimuli including chemotherapeutic agents, UV irradiation, and
calcium ionophores (5, 8, 9). The importance of Mcl-1 to macrophage survival has been confirmed in Mcl-1 transgenic mice and
by antisense inhibition in human macrophages (2, 10).
Antiapoptotic Bcl-2 family members exert their effect in part
by maintaining mitochondrial homeostasis and inhibiting
mitochondrial membrane permeabilization (MMP) (11). Mcl-1 is
found in mitochondrial-enriched cell fractions and can heterodimerize with proapoptotic Bcl-2 family members, such as Bax and
Bak, to prevent MMP (8, 12). Loss of Mcl-1 is an apical event in
the apoptotic cascade, as illustrated by its downregulation during
UV-induced or adenoviral protein E1A–induced apoptosis (12, 13).
Mcl-1 is subject to differential splicing, resulting in the generation of proapoptotic splice variants (14, 15). Mcl-1 is, therefore, an
ideal regulator of cell viability during rapidly evolving conditions
of cell stress and could allow the dynamic changes in cell viability
required during bacterial infection.
The most extensively studied model of host-mediated macrophage apoptosis involves the chronic intracellular pathogen
Mycobacterium tuberculosis, in which apoptosis limits bacterial
replication and, conversely, intracellular replication is prolonged
by inhibiting apoptosis (4, 16). Mcl-1 expression is upregulated
in macrophages by M. tuberculosis and inhibits host-mediated
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Figure 1
Mcl-1 protein levels demonstrate biphasic variation in association with pneumococcal infection of macrophages. (A) Total RNA was extracted
from MDMs 20 hours after mock infection (Spn–) or infection with pneumococci (Spn+), and Mcl-1 mRNA was detected by RNase protection
assay. The results presented are typical of 5 donors tested, but the duration of mRNA elevation varied among donors. L32 and GAPDH served
as loading controls. (B) Western blot of total protein from MDMs at the indicated time points after infection, probed with anti–Mcl-1 and antiactin antibodies. Data are representative of 7 independent experiments. (C) Mcl-1 band density from a series of MDMs as in B, quantified by
densitometry (n = 7). P < 0.05, Mcl-1 at 6 hours vs. 12 hours; P < 0.001, 6 hours vs. 20 hours; Student’s t test. (D) Levels of nuclear apoptosis
in the same series of MDMs as in C. P < 0.001, apoptosis at 6 hours vs. 16 hours, Student’s t test.

apoptosis, hence promoting mycobacterial survival and chronic
intracellular persistence (16). We have characterized a different
model of host-mediated macrophage apoptosis involving Streptococcus pneumoniae (the pneumococcus). This model does not exhibit
chronic intracellular persistence of bacteria (17, 18). Instead, bacteria are effectively eliminated through a response that proceeds in 2
phases: an initial period of macrophage viability and intracellular
bacterial killing, followed after 14–16 hours by apoptosis induction and clearance of bacteria. Inhibition of the latter phase of
apoptosis induction reduces bacterial clearance in vitro and in vivo
(17, 18). This model therefore allows analysis of both phases of the
macrophage response to bacterial infection.
We used a model of pneumococcal-associated host-mediated
macrophage apoptosis to test the hypothesis that Mcl-1 is critical
to both initial maintenance of cell viability and subsequent induction of apoptosis. Mcl-1 was upregulated in association with the
retention of cell viability after initial bacterial phagocytosis. Mcl-1
was subsequently downregulated, and a protein of approximately
34 kDa with an electrophoretic mobility corresponding to a novel
proapoptotic BH3-only splice variant Mcl-1Exon-1 was upregulated,
during the initiation of MMP and induction of apoptosis. These
changes in Mcl-1 expression have a role in the response to infection, as macrophages from transgenic mice overexpressing Mcl-1
demonstrated delayed MMP and impaired bacterial clearance in
vitro. Mcl-1 transgenic mice demonstrated less effective clearance
of bacteria from the lung in vivo. These findings demonstrate the
importance of an Mcl-1–regulated switch from macrophage viability to apoptosis for optimal host defense.
360
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Results
A biphasic response in monocyte-derived macrophage expression of Mcl-1 protein is observed after phagocytosis of pneumococci. We have previously demonstrated that after phagocytosis of pneumococci, an initial period
of macrophage viability is followed by apoptosis (17). To investigate
whether changes in Mcl-1 transcription occurred in macrophages
in response to exposure to pneumococci, we performed RNase protection assays. Mcl-1 mRNA was upregulated upon pneumococcal
infection (Figure 1A). To correlate Mcl-1 protein expression with
macrophage survival and death, we serially measured Mcl-1 expression in monocyte-derived macrophages (MDMs) from 7 donors 6–20
hours after infection. To take account of the interdonor variability
inherent to MDMs, both a representative Western blot and a summary graph depicting protein expression for all 7 donors are presented,
and protein expression is compared with the number of apoptotic
cells at each time point (Figure 1, B–D). Mcl-1 levels were upregulated
in infected MDMs compared with mock-infected MDMs for as long
as 14 hours after infection. After this time point, all donors demonstrated a progressive decline until Mcl-1 levels dropped below those
observed in mock-infected MDMs. The time at which this occurred
varied among donors, and the time at which Mcl-1 started to decline
best predicted the onset of apoptosis in infected cultures (Figure 1D).
To examine whether the alterations in Mcl-1 expression were part of
a general alteration in antiapoptotic Bcl-2 proteins, we also examined
Bcl-xL but found it to be unaltered (see data in Figure 4A).
Decreased Mcl-1 protein expression is associated with MMP during pneumococcal-associated MDM apoptosis. MMP, inhibited by
antiapoptotic Bcl-2 family members, occurs upstream of caspase
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Figure 2
Mitochondrial features of apoptosis are observed in macrophages infected with pneumococci. (A) Western blot of the cytosolic and mitochondrial
(Mit) fractions from MDMs at the indicated time points after infection with pneumococci or mock infection probed with anti–cytochrome c and
anti-actin antibodies. Results are derived from 2 donors and are representative of 2 independent experiments. (B) Western blot of the cytosolic
fractions from MDMs 20 hours after infection in the presence (+) or absence (–) of zVADfmk or N-benzyloxycarbonyl–Phe-Ala fluoromethyl
ketone (zFA) probed with anti–cytochrome c and anti-actin antibodies. Results are derived from 2 donors and are representative of 2 independent experiments. (C) MDMs were stained with JC-1 and Hoechst 33342 (Ho33342) 20 hours after infection. Loss of Δψm is represented as a loss
of punctate red staining, and nuclear morphology is detected by Hoechst 33342 staining. Data are representative of 3 donors. (D) Histograms
representing Δψm of MDMs at the indicated time points after infection, stained with JC-1. The percentage of cells with preservation of Δψm (indicated by the M1 marker) is shown. Results are representative of 3 independent experiments. (E) Western blot of nuclear fractions from MDMs
20 hours after infection, probed with anti-AIF and Histone H1 antibodies. Data are representative of 3 independent experiments.

activation in many pathways of programmed cell death (11). MMP is
characterized by loss of mitochondrial inner transmembrane potential (Δψm) and the mitochondrial release of intermembrane proteins
such as cytochrome c and apoptosis-inducing factor (AIF) (11, 19).
Cytochrome c translocation was observed in infected MDMs 14–16
hours after infection, and actin degradation was a feature of the late
stages of apoptosis but occurred after translocation of cytochrome
c and downregulation of Mcl-1 (Figure 2A). To exclude the possibility that mitochondrial features of apoptosis are a consequence
of a caspase amplification loop and occur downstream of caspase
activation (11), we determined the relationship of mitochondrial
permeability transition to caspase activation. Treatment with a pancaspase inhibitor, N-benzyloxycarbonyl–Val-Ala-Asp (O-methyl)
fluoromethyl ketone (zVADfmk), did not suppress cytochrome c
translocation (Figure 2B), suggesting that it occurs independently
of caspase activation. Loss of Δψm is also a feature of pneumococcalassociated macrophage apoptosis and is detected prior to nuclear
fragmentation (Figure 2C). Loss of Δψm showed the same kinetics
as cytochrome c translocation (Figure 2D) and was not prevented
by caspase inhibition (data not shown). AIF has been implicated
in pneumococcal-associated neuronal cell death (20). Nuclear fractions from pneumococcal-infected (but not mock-infected) MDMs
contained AIF and exhibited histone H1 degradation (Figure 2E).
The Journal of Clinical Investigation

The earliest features of MMP were coincident with the initial decline
in peak Mcl-1 protein expression, emphasizing that downregulation
of Mcl-1 was an early event in apoptosis induction.
Production of a novel BH3-only isoform of Mcl-1 is a feature of
pneumococcal-associated macrophage apoptosis. Analysis of Mcl-1 protein
expression in MDMs after pneumococcal infection revealed induction of an additional band of approximately 34 kDa on Western
blots probed with anti–Mcl-1 antibody (Figure 3A). In the series
of MDMs derived from 7 different donors, expression of the band
of approximately 34 kDa occurred from 12 hours after infection
and prior to onset of MMP. Treatment of infected MDM cultures
with the transcription inhibitor actinomycin D blocked expression of this protein (data not shown). We and others have shown
that altered splicing of the Mcl-1 gene can result in production of
a BH3-only proapoptotic protein (14, 15). The band of approximately 34 kDa detected in SDS-PAGE from infected MDMs exhibited a higher electrophoretic mobility than the in vitro translation
product of the Mcl-1S/ΔTM splice variant, but a migration similar
to that of the product of the Mcl-1Exon-1 splice variant (Figure 3B).
Mcl-1Exon-1 is the product of an mRNA that retains intron 1 and
contains 230 amino acids that are shared with full-length Mcl-1
and Mcl-1S/ΔTM plus an additional 4 amino acids (Figure 3C) (C.D.
Bingle, unpublished observations). Upregulation of this isoform in
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Figure 3
Pneumococcal infection of macrophages results in increased expression of a proapoptotic Mcl-1 isoform. (A) Western blot of total protein from
MDMs at the indicated time points after infection with pneumococci, probed with anti–Mcl-1 and anti-actin antibodies showing the appearance
of the band of approximately 34 kDa. The donor is representative of 1 of the series in Figure 1C. The mean levels of nuclear apoptosis at each
time point for this donor are indicated. (B) Western blot of total protein from U937 cells or MDMs (3 donors in 3 separate experiments) 20 hours
after infection with pneumococci or mock infection and U937 cells transfected with Mcl-1Exon-1 or empty vector probed with anti–Mcl-1 antibody,
with in vitro translation of Mcl-1, Mcl-1S/ΔTM, and Mcl-1Exon-1 as standards. (C) Genomic organization of Mcl-1 and Mcl-1Exon-1. The filled regions
represent the coding region of the 2 transcripts. (D) Percentage of nonviable infected or mock-infected U937 cells 16 hours after nucleofection
with vectors containing full-length Mcl-1, Mcl-1Exon-1, Bax, or empty vector. Results represent the analysis of 3 separate experiments. P < 0.05,
Spn– Mcl-1 vs. Spn– Mcl-1Exon-1; P < 0.05, Spn+ Mcl-1 vs. Spn+ Mcl-1Exon-1; Student’s paired t test. (E) Percentage of EGFP-positive cells demonstrating features of apoptosis after DAPI staining in the same experiments as in D. P < 0.05, Spn– Mcl-1 vs. Spn– Mcl-1Exon-1; P < 0.05, Spn+
Mcl-1 vs. Spn+ Mcl-1Exon-1; P < 0.05, Spn+ empty vector vs. Spn+ Mcl-1; Student’s paired t test.

response to infection was confirmed in the human monocytic cell
line U937, where transfection with a construct encoding Mcl-1Exon-1
or infection with pneumococci resulted in expression of an identical
34-kDa protein that was distinct from Mcl-1S/ΔTM (Figure 3B). The
proapoptotic function of Mcl-1Exon-1 was demonstrated in mockinfected and pneumococcal-infected U937 cells, where transfection
with a construct encoding Mcl-1Exon-1 both decreased cell viability
and increased apoptosis (Figure 3, D and E). Levels of apoptosis in
cells transfected with Mcl-1Exon-1 were comparable to those in cells
transfected with the proapoptotic Bcl-2 family member Bax. Furthermore, Mcl-1 transfection significantly decreased the percentage
of apoptotic cells among the population positive for enhanced GFP
(EGFP) after pneumococcal infection, as compared with transfection
with empty vector. These results demonstrate the interplay between
full-length Mcl-1 and Mcl-1Exon-1.
Mcl-1 contains caspase cleavage sites, and 4 caspase cleavage products of 17–28 kDa in size have been described (21). However, treatment with zVADfmk failed to alter the abundance of Mcl-1Exon-1
(Figure 4A). Similarly, caspase inhibition did not prevent the
decrease in Mcl-1 expression associated with pneumococcal
infection (data not shown). To exclude the possibility that other
proteases active in infected MDMs might generate the isoform of
Mcl-1 that was approximately 34 kDa, we treated cultures with
inhibitors of cysteine or serine proteases, but none resulted in
decreased expression of the protein (data not shown). Subcellular
fractionation demonstrated that Mcl-1Exon-1, like Mcl-1, was localized to the mitochondrial membrane, despite loss of the carboxyl
hydrophobic tail associated with mitochondrial localization of
the full-length protein (6) (Figure 4B). A small amount of Mcl-1
362
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was also apparent in the cytosolic fraction of mock-infected cells, but
this became undetectable by the time cytochrome c first translocated
to the cytoplasm. Mcl-1 downregulation can be a feature of cell stress
pathways in which p53 accumulates (12). To determine whether
Mcl-1Exon-1 expression is also induced by stimuli that induce apoptosis
by downregulating full-length Mcl-1, we examined the effect of UV
treatment on MDMs (13). As expected, UV irradiation induced
nuclear fragmentation in MDMs (Figure 4C) and p53 upregulation
(Figure 4D). Although UV irradiation was associated with Mcl-1
downregulation, there was no evidence of production of Mcl-1Exon-1
at any time point following UV exposure, suggesting that production
of Mcl-1Exon-1 is not a feature of UV-mediated MDM apoptosis.
Proteasome-mediated degradation of Mcl-1 occurs in pneumococcalassociated macrophage apoptosis. Mcl-1 is degraded by the ubiquitinproteasome pathway (13). Mcl-1 levels were increased in cell
lysates following treatment with the proteasome inhibitor carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), regardless of
whether they were mock-infected or infected (Figure 5A). At
20 hours after infection, proteasome inhibition with MG-132
increased levels of Mcl-1, although not to the same level as
observed in mock-infected cultures, suggesting that proteasomal
degradation by this pathway is not the sole explanation for
loss of Mcl-1 protein. However, the increased levels of Mcl-1
after proteasome inhibition were associated with decreased
cytochrome c translocation to the cytosol in pneumococcalinfected MDMs (Figure 5B). Furthermore, proteasome inhibition in pneumococcal-infected MDMs decreased nuclear features
of apoptosis (Figure 5C). Although proteasome inhibition can
reduce degradation of multiple antiapoptotic proteins in addi-
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Figure 4
Mcl-1 Exon-1 expression is an upstream event in pneumococcal-associated but not UV-associated macrophage apoptosis. (A) Western blot of total protein from MDMs 20 hours after infection in the presence (+) or absence (–) of zVADfmk (zVAD) or N-benzyloxycarbonyl–Phe-Ala fluoromethyl ketone
(zFA), probed with anti–Mcl-1, anti–Bcl-xL, and anti-GAPDH antibodies. Data is representative of 4 donors. (B) Western blot of membrane and nuclear
fractions from MDMs 20 hours after infection, probed with anti–Mcl-1 antibody. Data represent 2 donors and 3 independent experiments. (C) Nuclear
morphology, detected by DAPI staining, in control MDMs (left panel) or MDMs 12 hours after UV irradiation (right panel). Levels of apoptosis were 1%
in control MDMs and 34% in UV-irradiated MDMs. (D) Western blot of total protein from MDMs at the indicated time points after UV irradiation, probed
with anti–Mcl-1, anti-p53, and anti-actin antibodies. The asterisks mark the expected positions of Mcl-1Exon-1. Data are representative of 3 donors.

tion to Mcl-1 (13), these results suggest that proteasome-mediated degradation of Mcl-1 contributes to the loss of macrophage
viability following phagocytosis of pneumococci.
Bone marrow–derived macrophages from Mcl-1 transgenic mice demonstrate decreased apoptosis after pneumococcal infection. To further test the
concepts that Mcl-1 contributes to the switch in macrophage phenotype and that abrogating this switch might negatively affect clearance
of bacteria, we performed experiments with bone marrow–derived
macrophages (BMDMs) derived from Mcl-1 transgenic mice or their
nontransgenic littermates (10). Lysates from transgenic mice, but not
those from nontransgenic mice, reacted with an anti–human Mcl-1
antibody that does not detect murine Mcl-1 (Figure 6A). Transgenic
BMDMs exposed to pneumococci also demonstrated preservation
of Δψm (Figure 6, B and C), decreased translocation of cytochrome c
from the mitochondria (data not shown), and fewer nuclear changes
indicative of apoptosis than did nontransgenic BMDMs (Figure 6,
D and E). Pneumococcal infection of BMDMs resulted in a decrease
in expression of the Mcl-1 transgene (Figure 6F). Mcl-1Exon-1 protein

was also found in the lysates of BMDMs from Mcl-1 transgenic mice
after pneumococcal infection but not after mock infection (data
not shown). In keeping with this decreased expression of Mcl-1
after infection and the rapid turnover of Mcl-1 (6, 7), the decreased
apoptosis observed in transgenic BMDMs represented a delay in
apoptosis rather than a sustained inhibition, similar to previous
observations with Mcl-1 (8, 10). The preservation of Δψm apparent at
14–18 hours was no longer detectable at 20 hours after infection, and
the lack of nuclear apoptosis at 20 hours disappeared by 48 hours
after infection in transgenic BMDMs (data not shown).

Figure 5
Proteasome-mediated degradation of Mcl-1 is associated with
pneumococcal-associated macrophage apoptosis. (A) Western blot of
total protein obtained from MDMs 12 hours and 20 hours after mock
infection or infection with pneumococci in the presence or absence of
the proteasome inhibitor MG-132, probed with anti–Mcl-1 and antiactin antibodies. Data are representative of 4 donors in 2 independent
experiments. (B) Western blot of the cytosolic fractions from MDMs
20 hours after infection in the presence or absence of MG-132 probed
with anti–cytochrome c and anti-actin antibodies. Results are representative of 3 donors from 2 independent experiments. (C) MDMs
were incubated in the presence or absence of MG-132, and nuclear
features of apoptosis were recorded 20 hours after infection. Results
were obtained from 6 donors tested in duplicate. Dunn’s multiple comparison test: MDMs infected with pneumococci without MG-132 vs.
with MG-132, P < 0.05. Data are representative of 3 experiments.
The Journal of Clinical Investigation
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Figure 6
Macrophages from Mcl-1 transgenic mice have delayed apoptosis. (A) Western blot of total protein extracted from BMDMs from nontransgenic
mice (Non-Tg) and mice transgenic for human Mcl-1 (Tg) and probed with anti–human Mcl-1 and anti-actin antibodies. (B) BMDMs from
nontransgenic and transgenic mice were stained with JC-1 14 hours after mock infection or infection with pneumococci. Data are representative of 3 experiments. (C) Histograms representing Δψm of BMDMs from nontransgenic and transgenic controls 14 hours after infection, stained
with JC-1. Results are representative of 3 independent experiments. (D) Nuclear morphology, detected by DAPI staining, in BMDMs from
nontransgenic and transgenic mice 20 hours after infection. (E) Nuclear features of apoptosis were recorded from BMDMs from transgenic or
nontransgenic controls 20 hours after infection. P < 0.05, BMDMs infected with pneumococci from transgenic vs. nontransgenic, Dunn’s multiple
comparison test. Results represent 3 experiments. (F) Western blot of total protein from BMDMs from nontransgenic and transgenic mice 20
hours after infection, probed with anti–human Mcl-1 and anti-actin antibodies.

Clearance of pneumococci from the lung of Mcl-1 transgenic mice. We have
previously documented that caspase activation not only contributes
to apoptosis induction in macrophages following pneumococcal
phagocytosis (22), but also enhances bacterial clearance (17). In
association with delayed apoptosis in BMDMs from Mcl-1 transgenic mice, we also observed an increased viability of intracellular
pneumococci (Figure 7A). We have previously described a mouse
model of pulmonary pneumococcal infection in which apoptosis
of alveolar macrophages (AMs) contributes to optimal bacterial
clearance (18). Using this model, we instilled pneumococci into the
lungs of transgenic or nontransgenic mice and measured apoptosis
in AMs 14 hours after infection. Transgenic mice had significantly fewer apoptotic AMs (Figure 7, B and C) and significantly
less efficient clearance of bacteria from the lungs (Figure 7D). All
nontransgenic mice cleared 104 CFU of pneumococci from the
lung, but at this dose, transgenic mice had detectable numbers of
bacteria in the lung. In addition, all transgenic mice with more than
102 CFU in the lung developed bacteremia, a finding not seen in the
nontransgenic mice. When the inocula of bacteria were increased
to the threshold at which AM host defenses become overwhelmed,
nontransgenic mice no longer cleared bacteria completely, but their
364
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mean bacterial colony count was still lower by a factor of greater
than 1 on a log scale. For the small number of mice tested (n = 3–4),
however, this result did not reach statistical significance. Overall,
these results show that AM apoptosis is decreased in Mcl-1 transgenic mice after pneumococcal infection and that this is associated
with a significant impairment of bacterial clearance.
Discussion
Mcl-1 protein expression regulates macrophage transition from resistance
to susceptibility to apoptosis during pneumococcal infection. To contribute optimally to host defense, macrophages demonstrate
biphasic susceptibility to apoptosis. Initial resistance to apoptosis
in the face of proapoptotic host and microbial factors allows the
macrophages to contribute to innate immunity (3, 23), but subsequent induction of apoptosis facilitates bacterial clearance and
minimizes inflammation (18). The molecular events associated
with this transition are unknown, and the present research has
stemmed from our interest in identifying factors that regulate
this switch in macrophage phenotype.
We focused on the model of host-mediated macrophage apoptosis
during pneumococcal infection, because it is characterized by initial
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Figure 7
Mcl-1 transgenic mice demonstrate decreased AM apoptosis and
decreased bacterial clearance from the lung. (A) Intracellular killing assays
were performed in BMDMs from Mcl-1 transgenic and nontransgenic
controls 14 hours after infection. Results are representative of 4 separate
experiments. P < 0.05, transgenic vs. nontransgenic; Wilcoxon signed
rank test. Transgenic and nontransgenic mice received an intratracheal
instillation of the indicated dose of pneumococci. (B and C) Percentage apoptotic macrophages in bronchial alveolar fluid from transgenic
vs. nontransgenic mice after instillation of 104 CFU pneumococci as
assessed by (B) Annexin V/ToPro 3 staining and flow cytometry (P < 0.01;
n = 6–8) and (C) nuclear morphology on cytospins (P < 0.01; n = 6–8). (D)
Bacterial CFU in lungs of transgenic vs. nontransgenic mice (104 CFU,
P < 0.05, n = 6–8; 105 CFU, P > 0.05, n = 3–4).

macrophage viability and subsequent macrophage apoptosis
(17, 18). A tightly regulated biphasic pattern in macrophage susceptibility to apoptosis is essential for optimal killing of bacteria
in this model. Pneumococci are innately resistant to phagocytosis
and challenge the capacity of host defenses to clear bacteria successfully (24). Nevertheless, phagocytosis of opsonized bacteria by
macrophages results in clearance of bacteria without intracellular
persistence and is associated with macrophage apoptosis (22, 24).
In contrast to mycobacteria, which tend to persist intracellularly
(25, 26), the pneumococcal model of host-mediated macrophage
apoptosis involves phagocytosis and acute bacterial killing without prolonged intracellular survival (22), enabling investigation of
biphasic susceptibility to apoptosis.
Mcl-1 has been identified as a specific determinant of the resistance of macrophages to apoptosis and acts during periods of
changing cell phenotype (2, 5). As shown in this work, upregulation
of Mcl-1 mRNA was associated with sustained macrophage viability for at least 14 hours after exposure to pneumococci. As proof of
concept, transfection of U937 cells with Mcl-1 decreased the level
of apoptosis after pneumococcal infection. Furthermore, transgenic mice overexpressing Mcl-1 exhibited reduced apoptosis after
pneumococcal infection, both in BMDMs in vitro and in AMs in vivo.
Mcl-1 upregulation in macrophages is a feature of mycobacterial
infection (16), and enhanced Mcl-1 gene transcription has been identified in brain endothelium during infection with the group B streptococcus, an organism closely related to the pneumococcus (27). It is
plausible that Mcl-1 upregulation may be utilized by a broad range
of cell types to prevent apoptosis during infection (28).
Bcl-2 family proteins protect against apoptosis during conditions
of increased cell stress, including nitrosative or oxidative stress
(29, 30), which prevail in macrophages loaded with bacteria (31).
Mice deficient in adenine nucleotide translocator 1 demonstrate
oxidative stress and upregulate Mcl-1 (32). In the first 12–14 hours
after phagocytosis of pneumococci, Mcl-1 aids maintenance of
mitochondrial homeostasis despite increasing cell stress. Following this period of macrophage viability, Mcl-1 expression declines,
and signs of MMP and apoptosis are observed. Even BMDMs
from Mcl-1 transgenic mice exhibited only a delay in MMP. Mcl-1
The Journal of Clinical Investigation

downregulation is a feature of cell stress pathways (13), and a DNA
damage–response pathway that mediates apoptosis in association
with Mcl-1 downregulation with enhanced Bak-Bax heterodimerization has recently been described in HeLa cells infected with
adenovirus and contributes to antiviral host defense (12). Late
decreases in Mcl-1 protein levels were the result of both translational downregulation, and active proteasomal degradation–cellular stress pathways may influence both these processes (12, 13).
Increased protein degradation was a constant finding, whereas the
timing of downregulation of mRNA was variable with some donors
showing decreased mRNA only after 20 hours. The critical determinant of the onset of apoptosis induction in this model seemed
to be the timing of initial decline of Mcl-1 expression from peak
levels rather than the time at which the absolute level of Mcl-1 fell
below the level expressed in mock-infected cells. Nitrosative/oxidative stress can trigger apoptosis in DNA-damage pathways (33), and
we have recently shown that NO production contributes to MMP in
pneumococcal-associated macrophage apoptosis (34). Mcl-1 may be
downregulated in response to cellular stresses such as nitrosative/
oxidative stress, nucleotide depletion, or accumulating DNA damage in macrophages loaded with pneumococci. It has been reported
that accumulating nitrosative stress in cells initially does not induce
apoptosis, as glycolytic ATP production maintains viability, but once
this source of ATP production fails, oxidative stress supervenes and
MMP results (35). Therefore the initial mitochondrial protection
provided by Mcl-1 is likely to be overwhelmed by the combination
of Mcl-1 downregulation and accumulating cell stress.
Generation of a novel BH3-only isoform of Mcl-1 is associated with
macrophage apoptosis during pneumococcal infection. We documented
upregulation of a novel isoform of Mcl-1 of approximately 34
kDa that is compatible with Mcl-1Exon-1, a BH3-only protein, after
pneumococcal infection (but not after UV-induced apoptosis).
Expression of this protein required active transcription but was
not blocked by inhibitors of caspases, cathepsins, calpains, or serine
proteases. Transfection of Mcl-1Exon-1 into U937 cells confirmed that
this protein was proapoptotic and had effects comparable to those
of Bax in enhancing apoptosis in both the absence or the presence
of pneumococcal infection. Alternative splicing is a feature of many
Bcl-2 proteins, and generation of an isoform in association with
retention of an intron and generation of an open reading frame
arising from a continuous genomic sequence has been described
for the Bcl-x isoform Bcl-xβ (36). Although no specific binding partners of Mcl-1Exon-1 have been identified, it is interesting to note that
another isoform of Mcl-1, Mcl-1S/ΔTM (14), binds (and potentially
neutralizes) full-length Mcl-1 (15). In addition, the localization of
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Mcl-1Exon-1 (which lacks the C-terminal transmembrane domain) to
the mitochondrial fraction, suggests that it may interact with Bcl-2
family members already anchored to the mitochondrial membrane.
Activated BH3-only proteins can bind antiapoptotic Bcl-2 proteins
releasing Bak/Bax from inhibition or directly activating Bak-Bax
for MMP induction (37, 38).
Many Bcl-2 family isoforms have been identified and have been
best characterized in BH3-only proteins such as Bim (39). However, these isoforms have been described in transformed cell lines or
experiments involving cloning systems (40). There has been little
information on the expression of Bcl-2 family isoforms during physiologic events such as infection or inflammation. The only reports
concern the induction of 3 murine A1 isoforms in mice exposed
to bacillus Calmette-Guerin, although these isoforms arise from
transcription of 3 separate genes and do not arise from differential splicing (41). In contrast, in the present system, the differential
splicing of a single gene would result in expression of an isoform
that opposes the function of the full-length protein. Importantly,
this isoform is not expressed by mock-infected macrophages, and
its putative expression in infected cells occurs before Mcl-1 transcription starts to fail, suggesting that the splicing event is not the
result of failure of gene transcription. The opposing functions of
full-length Mcl-1 and Mcl-1Exon-1 were confirmed by transfection of
U937 cells, illustrating that differential splicing of the Mcl-1 gene is
a key event in regulating susceptibility of macrophages to apoptosis
during infection. Thus, bacterial infection is a stimulus for alternative splicing of Bcl-2 family genes.
The importance of tightly regulating the onset of apoptosis induction in
macrophage-mediated antibacterial defense. The dynamic regulation
of Mcl-1 isoform expression apparently determines the timing of
MMP and the switch in macrophage susceptibility to apoptosis
during pneumococcal infection. The importance of this pathway to the host is illustrated by the variety of strategies employed
by bacteria to subvert this process, for instance, by initiating
apoptosis downstream of MMP (42). Bacteria may induce macrophage apoptosis in the first few hours after exposure, killing the
macrophages before key host defense functions are completed
(43). Although these forms of pathogen-mediated apoptosis most
often involve direct caspase activation, induction of Mcl-1 degradation by Shiga toxin has been described in endothelial cells
(44). In contrast, M. tuberculosis delays host-mediated macrophage
apoptosis to prolong intracellular survival (45). Although a variety
of mechanisms, including modulation of death receptor signaling,
have been implicated in this process (45), evidence of upregulation
of antiapoptotic Bcl-2 proteins, including Mcl-1 and A1, has been
reported (16, 41). Inhibition of MMP in macrophages during bacterial infection has also been identified as a mechanism by which
intracellular bacteria ensure prolonged survival (42).
Mcl-1 probably also contributes to the regulation of apoptosis
in neutrophils during infection, as it has been shown to mediate apoptosis inhibition by GM-CSF, IL-1β, or bacterial
lipopolysaccharide (46). Furthermore, proteasome inhibition
delays neutrophil apoptosis in association with decreased turnover of Mcl-1 (47). Upregulation of Mcl-1 can delay apoptosis in
neutrophils during Toxoplasma gondii infection, demonstrating
its role in prolonging survival of phagocytes engaged in critical host defense functions (48). In view of the important role of
neutrophils in successful resolution of pneumococcal pneumonia
(49), it is likely that levels of Mcl-1 expression in neutrophils also
contribute to the outcome of pneumococcal infection.
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Although altered Mcl-1 expression in cells during exposure to
microorganisms has been described previously (16, 27, 44, 48), the
functional consequences of altered Mcl-1 expression in vivo during
the host response to infection have not previously been demonstrated. We demonstrate that delaying the induction of apoptosis by
overexpressing Mcl-1 in macrophages from Mcl-1 transgenic mice
reduces AM apoptosis as well as the efficiency of bacterial clearance in a subclinical model of pneumococcal infection. Because this
model is not associated with significant recruitment of neutrophils
and AMs are the major source of apoptotic cells in this model (18),
it is likely that AMs — and by extension, AM apoptosis — indeed play
a critical role in antibacterial host defense. Thus, inhibition of AM
apoptosis by 2 different experimental systems, namely overexpression
of Mcl-1 (this study) and caspase inhibition (18), is associated with
an increased likelihood of bacteremia, suggesting that AM apoptosis
has an important role in preventing invasive pneumococcal disease.
Factors activated during apoptosis induction could also contribute to antibacterial host defense by directly killing bacteria. Caspase
activation occurs downstream of Mcl-1 downregulation and MMP
in macrophages following pneumococcal infection. The identity of
the caspases involved requires delineation, but experiments with
caspase-1–deficient mice suggest that caspase-1 does not play a
role (H.M. Marriott and D.H. Dockrell, unpublished data). Loss of
MMP has been associated with increased ROS and NO production,
which could contribute to bacterial killing and/or provide an additional stimulus for caspase activation (50). These considerations
are important in optimizing the use of experimental therapies
such as NO synthase and caspase inhibitors (51, 52). Although they
may improve survival in models of overwhelming infection, they
could worsen the outcome in subclinical infection by delaying the
apoptosis phase necessary for optimal bacterial killing (18).
Conclusion. We provide evidence that pneumococcal-associated
macrophage apoptosis represents a host defense that is tightly
regulated by the dynamic alteration and pattern of Mcl-1 isoform
expression. Upregulation of full-length Mcl-1 initially maintains macrophage viability, while subsequent downregulation of
full-length Mcl-1 and upregulation of a proapoptotic isoform,
Mcl-1Exon1, triggers MMP. Transgene-enforced overexpression of
Mcl-1 delays the onset of apoptosis induction and impedes macrophage-mediated bacterial clearance.
Methods
Bacteria. Type 1 S. pneumoniae (WHO reference laboratory strain, SSISP; Statens Seruminstitut) were grown as previously described and opsonized in
RPMI (Sigma-Aldrich) containing 10% anti-pneumococcal immune serum
(22). In experiments involving murine cells, bacteria were opsonized in serum
from immunized mice with detectable antibodies against type 1 S. pneumoniae
(53). For in vivo infection, type 2 S. pneumoniae (D39 strain) were used (18).
Cells and infection. Human PBMCs were isolated from whole blood donated by healthy volunteers as previously described with informed consent
as approved by the South Sheffield Regional Ethics Committee of Royal
Hallamshire Hospital (Sheffield, United Kingdom) (22). Murine BMDMs
were obtained by culturing marrow from mice expressing human Mcl-1
as a transgene or from nontransgenic littermates (10). Marrow cells were
plated at 0.5 × 106 cells/ml and cultured as described in DMEM (SigmaAldrich) containing 10% FCS and 10% L929 conditioned medium (18). At
14 days, representative wells were scraped to determine the concentration
of BMDMs. U937 cells were cultured in RPMI plus 10% FCS, 2 mM GlutaMAX (Invitrogen Corp.), 10 mM HEPES (Invitrogen Corp.), 1 mM sodium
pyruvate (Invitrogen Corp.) and 4.5 g/l of glucose (Sigma-Aldrich). MDM
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or BMDM cultured for 14 days or U937 cells were infected with opsonized
S. pneumoniae at a MOI of 10 or mock-infected (22). In certain experiments,
10 μM MG-132 (Calbiochem) as a proteasome inhibitor; 50 μM zVADfmk
(Enzymes Systems Products) as a pan-caspase inhibitor; N-benzyloxycarbonyl–Phe-Ala fluoromethyl ketone (Enzyme Systems Products) as a control for zVADfmk; 50 μM ALLN (Calbiochem) as a calpain I and II inhibitor;
50 μM Cathepsin Inhibitor I (Calbiochem) as a cathepsin B, L, and S, and
papain inhibitor; or complete protease inhibitor cocktail (Roche) as a broad
spectrum serine and cysteine protease inhibitor was added 1 hour before
infection and after washing at 4 hours. Actinomycin D (5 μg/ml; SigmaAldrich) was added 4 hours after infection. For UV irradiation, MDMs were
exposed to 120 mJ/cm2 of irradiation (Stratalinker 1800; Stratagene).
Generation of MCL-1 expression constructs. Expression constructs containing Mcl-1WT and Mcl-1S/ΔTM sequences, pcDNA Bax, and insertless pCR3.1
vector were as described (14). For generation of the pCR3.1 Mcl-1Exon1 construct, the following primer pairs were used: Mcl-1 Kozak F 5′-GCCACCATGTTTGGCCTCAAAAGAAACGCG-3′, Mcl-1 EX1R 5′-GAATTCTTAATGAACCCGCTTACCTTG-3′, with genomic DNA as template. The
resulting fragments were excised from agarose gels, and the DNA was
extracted using the QIAEXII Gel Extraction Kit (Qiagen) and directly
cloned into pCR3.1 TOPO (Invitrogen Corp.).
SDS-PAGE and Western immunoblotting. Whole-cell extracts and cytosolic
and membrane fractions were extracted as described (34). For detection
of AIF in nuclear fractions, cells were lysed in buffer containing 20 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, 250 mM sucrose, and protease inhibitor cocktail as described (54).
The pellet was resuspended in lysis buffer (nuclear fraction). The supernatant was spun at 10,000 g for 15 minutes at 4°C. The pellet was resuspended in lysis buffer (mitochondrial fraction); the supernatant was
spun at 500,000 g for 1 hour at 4°C, and the resulting supernatant was
used as the cytosolic fraction. Protein was quantified using a modified
Lowry protocol (DC protein assay; Bio-Rad Laboratories), and equal protein was loaded per lane, either 25 μg of total protein or 10 μg of protein
from cell fractions. Samples were separated by SDS-PAGE (12% or 15%)
and blotted onto nitrocellulose membranes (Bio-Rad Laboratories) with
protein transfer confirmed by Ponceau S staining. Blots were incubated
overnight at 4°C with antibodies against Mcl-1 (rabbit polyclonal SC-19,
1:500; Santa Cruz Biotechnology Inc. or rabbit polyclonal, 1:1,000; BD
Biosciences), cytochrome c (mouse monoclonal, clone 7H8.2C12, 1:1,000;
BD Biosciences), Bcl-xL (rabbit polyclonal, 1:1,000; BD Biosciences), p53
(mouse monoclonal, clone DO-1; Santa Cruz Biotechnology Inc.), actin
(goat polyclonal, 1:500; Santa Cruz Biotechnology Inc. or rabbit polyclonal,
1:2,000; Sigma-Aldrich), GAPDH (mouse monoclonal, 1:2,000; Chemicon),
Histone H1 (AE-4, mouse monoclonal, 1:500; Santa Cruz Biotechnology
Inc.) or AIF (1:1,000) (19). Protein detection was done with HRP-conjugated secondary antibodies (Dako) and ECL (Amersham Pharmacia). Bands
were quantified using Image J 1.32 software (NIH), and after confirming
equivalence of Ponceau S staining for each time point, Mcl-1 bands were
compared with the mean of the mock-infected bands for that donor.
In vitro translation. To prepare Mcl-1 proteins, a coupled in vitro transcription/translation system (Promega) was used in accordance with the
manufacturer’s instructions using Mcl-1 constructs in pCR3.1.
RNase protection assay. Total RNA was harvested from MDMs cultured in 25-cm2 plastic flasks using guanidine isothiocyanate solution
(4 M guanidine isothiocyanate, 5 mM sodium citrate [pH 7.0], 0.1 M
β-mercaptoethanol [all Sigma-Aldrich]) and CsCl as previously described (55).
1. Sibille, Y., and Reynolds, H.Y. 1990. Macrophages
and polymorphonuclear neutrophils in lung defense
and injury. Am. Rev. Respir. Dis. 141:471–501.
2. Liu, H., Perlman, H., Pagliari, L.J., and Pope, R.M.

Assays were performed using 5 mg of RNA and the APO-2b probe set
according to the RiboQuant protocol (BD Biosciences).
Apoptosis detection. Nuclear morphology was examined on all cells by DAPI
(Molecular Probes) as previously reported (22). Apoptosis was estimated by
blinded reviewers who counted 300 cells per coverslip in duplicate samples
for the presence of condensed or fragmented nuclei. To detect loss of Δψm,
cells were stained in 250 μL RPMI containing 10 μM 5,5′,6,6′-tetrachloro1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide (JC-1) (Molecular
probes) and 2 μM Hoechst 33342 (Calbiochem) as a nuclear counterstain
for 30 minutes at 37°C. Coverslips were mounted and examined by fluorescent microscopy. Loss of Δψm was confirmed by loss of red punctate
staining. In these experiments, MDMs pretreated with 5 μM staurosporine
(Sigma-Aldrich) for 2 hours were used as a positive control. To quantify loss
of Δψm, 2 × 106 cells were stained with JC-1 as above, washed, scraped, and
analyzed by a FACSCalibur flow cytometer (BD Biosciences — Pharmingen).
At least 10,000 cells were analyzed for each experimental condition.
Transient transfection with Mcl-1 isoform constructs to assess effects on cell death.
pCR3.1-based vectors (0.5 μg) were transiently transfected into U937 cells
together with pcDNA Bax as a positive control, and empty pCR3.1 vector
as a negative control; 0.5 μg of vector expressing EGFP was cotransfected
as a reporter. Transfection was by nucleofection (Amaxa GmbH), in
accordance with the manufacturer’s protocol, 4 hours after infection.
Cytospin preparations were performed 16 hours after transfection, and
apoptosis was assessed as above.
Bacterial killing assay. The intracellular bacterial killing assay was performed at 14 hours as previously described (34) with quadruplicate wells
lysed for each data point.
In vivo infection. Mcl-1 transgenic mice or nontransgenic littermates were
infected by intratracheal instillation of 104 or 105 CFU type 2 S. pneumoniae,
as described previously (18). Mice were killed 14 hours after infection,
and bronchoalveolar lavage and lungs were collected. Bacterial numbers
in blood and lung and AM apoptosis, assessed by flow cytometry after
Annexin V-PE/ToPro 3 staining, or assessment of nuclear morphology
on cytospin preparations were as previously described (18). All animal
experiments were conducted in accordance with the Home Office Animals
(Scientific Procedures) Act of 1986 and was approved by the animal project
review committee of the University of Sheffield.
Statistics. Results are recorded as mean and SEM. Parametric or
nonparametric testing was performed with the indicated tests using Prism
4.0 software (GraphPad Inc.). Significance was defined as P < 0.05.
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